Trials show benefit of ‘on demand’ use of AZ’ asthma inhaler
AstraZeneca has unveiled data from two Phase III trials showing the benefit of using Symbicort Turbuhaler as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma.
Read More
